59834-05-8

Basic information

• Product Name: 4-(1,2,3-THIADIAZOL-4-YL)PHENOL
• Synonyms: 4-(1,2,3-THIADIAZOL-4-YL)BENZENOL;4-(1,2,3-THIADIAZOL-4-YL)PHENOL;4-(4-HYDROXYPHENYL)-1,2,3-THIADIAZOLE;4-(1,2,3-Thiadiazol-4-yl)phenol ,97%
• CAS NO: 59834-05-8
• Molecular Formula: C₈H₆N₂OS
• Molecular Weight: 178.21
• Mol File: 59834-05-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 105/0.75mm
• Flash Point: 162.2 °C
• Appearance: /
• Density: 1.38 g/cm³
• Vapor Pressure: 3.28E-05mmHg at 25°C
• Refractive Index: 1.653
• CAS DataBase Reference: 4-(1,2,3-THIADIAZOL-4-YL)PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,2,3-THIADIAZOL-4-YL)PHENOL(59834-05-8)
• EPA Substance Registry System: 4-(1,2,3-THIADIAZOL-4-YL)PHENOL(59834-05-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 59834-05-8(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C8H6N2OS/c11-7-3-1-6(2-4-7)8-5-12-10-9-8/h1-5,11H

Upstream product

• 99-93-4 4-Hydroxyacetophenone 
• 18212-22-1 4-(4-methoxy-phenyl)-[1,2,3]thiadiazole 
• 59834-03-6 N'-[1-(4-hydroxy-phenyl)-ethylidene]-hydrazinecarboxylic acid ethyl ester 
• 22107-31-9 4-hydroxyacetophenone semicarbazone 
• 543710-24-3 C₁₅H₁₆N₂O₃S 

Downstream Products

• 84260-61-7 4-(4'-N-Methylcarbamoyloxyphenyl)-1,2,3-thiadiazole 
• 1219829-95-4 n-hexylcarbamic acid 4-(1,2,3-thiadiazol-4-yl)phenyl ester 
• 1219829-96-5 dodecylcarbamic acid 4-(1,2,3-thiadiazol-4-yl)phenyl ester 
• 1219829-97-6 cyclopentylcarbamic acid 4-(1,2,3-thiadiazol-4-yl)phenyl ester 
• 1219829-98-7 cyclohexylcarbamic acid 4-(1,2,3-thiadiazol-4-yl)phenyl ester 
• 1219829-99-8 benzylcarbamic acid 4-(1,2,3-thiadiazol-4-yl)phenyl ester 
• 59834-07-0 3-[4-(1,2,3-thiadiazole-4-yl)phenoxy]-1,2-propenoxide 

Relevant articles and documents

Coupled Flavin-Iodine Redox Organocatalysts: Aerobic Oxidative Transformation from N-Tosylhydrazones to 1,2,3-Thiadiazoles

A bioinspired two-component redox organocatalyst system using 1,10-bridged flavinium and NH4I was developed to perform environmentally friendly aerobic oxidative ring formation of 1,2,3-thiadiazoles from N-tosylhydrazones and sulfur. The redox

1,2,3-Thiadiazoles with unsaturated side chains; synthesis, polymerization, and photocrosslinking

1,2,3-Thiadiazoles with polymerizable functionalities in the 4-position were synthesized as potential negative photoresists. The polymerization to soluble, film-forming materials must leave the heterocyclic rings intact, because they are needed for photocrosslinking reactions to give insoluble materials. 1,2,3-Thiadiazoles 1 cycloeliminate N2 on irradiation. The resulting 1,3-diradicals 2 have various options for stabilization processes leading to alkynes 3 or to higher heterocycles 5-12. The generation of atomic sulfur and its involvement in these subsequent reactions must be avoided. Therefore, systems like model compound 1a, in which the 1,3-diradicals form 2-methylene-1,3-dithioles (dithiafulvenes) 9 were selected here. Optimization gave ultimately two materials for application as photoresists. Monomer 1c could be polymerized in the presence of boron trifluoride to soluble 1c′, which on irradiation formed 1c″ as a cross-linked insoluble polymer. Furthermore, thiadiazole 1f was attached to polystyrene 26. The resulting soluble polymer 1i′ yielded the insoluble material 1i″ on irradiation. Georg Thieme Verlag Stuttgart.

Bita3 adrenergic receptor agonists and uses thereof

The instant invention provides β3 adrenergic receptor agonists of structural Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R1, R2, R3, R4, R5, R6, R7, R8, X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating β3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.